All In Biotech

Drug Trial Radar · NCT02323191

A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors

Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

221

Actual

Start

Jan 19, 2015

Primary completion

Aug 21, 2020

Study completion Aug 21, 2020

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1, open-label, multicenter, global study will evaluate the safety, pharmacokinetics, and activity of emactuzumab and atezolizumab administered in combination in participants with selected locally advanced or metastatic solid tumors that are not amenable to standard treatment. Participants who receive emactuzumab and atezolizumab will continue to receive study drug as long as they experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data, biopsy results (if available), and clinical status, or withdrawal of consent.

Conditions

  • Solid Cancers

Interventions

  • AtezolizumabDrug

    Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.

  • EmactuzumabDrug

    Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose Limiting Toxicities (DLTs)Time frame: 21 days
  2. Maximum Tolerated Dose (MTD) of EmactuzumabTime frame: 21 days
  3. Percentage of Participants With Adverse Events (AEs)Time frame: Baseline up to 3 years

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center; Medical Oncology

    New Haven, Connecticut

  • Massachusetts General Hospital.

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber - Harvard

    Boston, Massachusetts

  • Memorial Sloan-Kettering Cancer Center Breast & Imaging Center

    New York, New York

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • Centre Leon Berard; Departement Oncologie Medicale

    Lyon, France

  • Institut Claudius Regaud; Departement Oncologie Medicale

    Toulouse, France

  • Institut Gustave Roussy; Departement Oncologie Medicale

    Villejuif, France

  • Hospital del Mar; Servicio de Oncologia

    Barcelona, Spain

  • Centro Integral Oncológico Clara Campal Ensayos Clínicos START

    Madrid, Spain

  • Clinica Universitaria de Navarra; Servicio de Oncologia

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.